Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 6
1991 9
1992 14
1993 23
1994 30
1995 23
1996 23
1997 10
1998 17
1999 14
2000 7
2001 10
2002 5
2003 13
2004 10
2005 11
2006 7
2007 13
2008 9
2009 9
2010 16
2011 27
2012 43
2013 45
2014 89
2015 143
2016 232
2017 467
2018 723
2019 1150
2020 1956
2021 3218
2022 3623
2023 4268
2024 2041

Text availability

Article attribute

Article type

Publication date

Search Results

16,276 results

Results by year

Filters applied: . Clear all
Page 1
Axokine (Regeneron).
Preti A. Preti A. IDrugs. 2003 Jul;6(7):696-701. IDrugs. 2003. PMID: 12861475 Review.
Axokine, a second-generation neurotrophic factor that is related to ciliary neurotrophic factor (CNTF), is under development by Regeneron for the potential treatment of obesity and associated complications such as type 2 diabetes....
Axokine, a second-generation neurotrophic factor that is related to ciliary neurotrophic factor (CNTF), is under development by Regeneron …
Exome sequencing and analysis of 454,787 UK Biobank participants.
Backman JD, Li AH, Marcketta A, Sun D, Mbatchou J, Kessler MD, Benner C, Liu D, Locke AE, Balasubramanian S, Yadav A, Banerjee N, Gillies CE, Damask A, Liu S, Bai X, Hawes A, Maxwell E, Gurski L, Watanabe K, Kosmicki JA, Rajagopal V, Mighty J; Regeneron Genetics Center; DiscovEHR; Jones M, Mitnaul L, Stahl E, Coppola G, Jorgenson E, Habegger L, Salerno WJ, Shuldiner AR, Lotta LA, Overton JD, Cantor MN, Reid JG, Yancopoulos G, Kang HM, Marchini J, Baras A, Abecasis GR, Ferreira MAR. Backman JD, et al. Nature. 2021 Nov;599(7886):628-634. doi: 10.1038/s41586-021-04103-z. Epub 2021 Oct 18. Nature. 2021. PMID: 34662886 Free PMC article.
Allergic Endotypes and Phenotypes of Asthma.
Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Akar-Ghibril N, et al. J Allergy Clin Immunol Pract. 2020 Feb;8(2):429-440. doi: 10.1016/j.jaip.2019.11.008. J Allergy Clin Immunol Pract. 2020. PMID: 32037107 Free PMC article.
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Oláh J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Sarnaik AA, et al. J Clin Oncol. 2021 Aug 20;39(24):2656-2666. doi: 10.1200/JCO.21.00612. Epub 2021 May 12. J Clin Oncol. 2021. PMID: 33979178 Free PMC article.
A2BCD: a concise guide for asthma management.
Lommatzsch M, Brusselle GG, Levy ML, Canonica GW, Pavord ID, Schatz M, Virchow JC. Lommatzsch M, et al. Lancet Respir Med. 2023 Jun;11(6):573-576. doi: 10.1016/S2213-2600(22)00490-8. Epub 2023 Jan 27. Lancet Respir Med. 2023. PMID: 36716752 Review.
Atopic Dermatitis (Eczema).
Chovatiya R. Chovatiya R. JAMA. 2023 Jan 17;329(3):268. doi: 10.1001/jama.2022.21457. JAMA. 2023. PMID: 36648466 Free PMC article.
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R, Lockshin B, Meltzer S, Wang Z, Mannent LP, Amin N, Sun Y, Laws E, Akinlade B, Dillon M, Kosloski MP, Kamal MA, Dubost-Brama A, Patel N, Weinreich DM, Yancopoulos GD, O'Malley JT, Bansal A; participating investigators. Paller AS, et al. Lancet. 2022 Sep 17;400(10356):908-919. doi: 10.1016/S0140-6736(22)01539-2. Lancet. 2022. PMID: 36116481 Clinical Trial.
Dupilumab was well tolerated and showed an acceptable safety profile, similar to results in older children and adults. FUNDING: Sanofi and Regeneron Pharmaceuticals....
Dupilumab was well tolerated and showed an acceptable safety profile, similar to results in older children and adults. FUNDING: Sanofi and …
NT-3. Takeda/Regeneron/Amgen.
Urbanics R. Urbanics R. IDrugs. 2001 Jul;4(7):820-4. IDrugs. 2001. PMID: 15995939
Regeneron, in collaboration with Amgen, is developing neurotrophin-3 (NT-3), a neuronal growth factor, for the potential treatment of neuropathies, as well as Parkinson's disease (PD). ...By 1994, Amgen had begun phase I/II trials on behalf of Amgen-Regeneron Partne …
Regeneron, in collaboration with Amgen, is developing neurotrophin-3 (NT-3), a neuronal growth factor, for the potential treatment of …
IL-1 trap. Regeneron/Novartis.
Gabay C. Gabay C. Curr Opin Investig Drugs. 2003 May;4(5):593-7. Curr Opin Investig Drugs. 2003. PMID: 12833655 Review.
Regeneron and Novartis are co-developing the interleukin (IL)-1 antagonist IL-1 trap for the potential treatment of rheumatoid arthritis. ...
Regeneron and Novartis are co-developing the interleukin (IL)-1 antagonist IL-1 trap for the potential treatment of rheumatoid arthri …
16,276 results
You have reached the last available page of results. Please see the User Guide for more information.